×
About 6,723 results

ALLMedicine™ Helicobacter Pylori Infection Center

Research & Reviews  2,223 results

Association between salt intake and gastric atrophy by Helicobacter pylori infection: f...
https://doi.org/10.1007/s00394-023-03132-w
European Journal of Nutrition; Knaze V, Freisling H et. al.

Mar 26th, 2023 - Gastric atrophy (GA), usually linked to chronic infection with Helicobacter pylori (H. pylori), may over time evolve into gastric malignancy. Besides H. pylori, high salt intake may play a role in GA development. This study evaluates cross section...

Global burden of gastric cancer: epidemiological trends, risk factors, screening and pr...
https://doi.org/10.1038/s41571-023-00747-0
Nature Reviews. Clinical Oncology; Thrift AP, Wenker TN et. al.

Mar 25th, 2023 - Gastric cancer remains a major cause of cancer-related mortality worldwide. The temporal trends for this malignancy, however, are dynamic, and reports from the past decade indicate important declines in some regions and demographic groups, as well...

Vonoprazan is non-inferior to proton pump inhibitors in bismuth-containing quadruple th...
https://doi.org/10.1111/1751-2980.13166
Journal of Digestive Diseases; Wang J, Li YY et. al.

Mar 25th, 2023 - The efficacy of vonoprazan compared with that of proton pump inhibitors in clarithromycin-based bismuth-containing quadruple therapy has not been fully demonstrated. This study aimed to evaluate the efficacy and safety of vonoprazan-based versus p...

YouTube as a source of information on Helicobacter pylori: Content and quality analysis.
https://doi.org/10.1111/hel.12971
Helicobacter Ergenç M, Uprak TK

Mar 22nd, 2023 - Helicobacter pylori infection is the most common cause of infectious diseases worldwide, and management is a current and vital problem for physicians and patients. One of the online platforms that people use most to access health information is Yo...

Hybrid, high-dose dual and bismuth quadruple therapies for first-line treatment of Heli...
https://doi.org/10.14309/ajg.0000000000002255
The American Journal of Gastroenterology; Hsu PI, Chen KY et. al.

Mar 21st, 2023 - In this multicenter, open-label, randomized trial, we recruited adult H. pylori-infected patients from nine centers in Taiwan. Subjects were randomly assigned (1:1:1) to 14-day hybrid therapy, 14-day high-dose dual therapy or 10-day bismuth quadru...

see more →

Guidelines  8 results

United European Gastroenterology (UEG) and European Society for Neurogastroenterology a...
https://doi.org/10.1111/nmo.14238
Neurogastroenterology and Motility : the Official Journal... Wauters L, Dickman R et. al.

Sep 30th, 2021 - Functional dyspepsia (FD) is one of the most common conditions in clinical practice. In spite of its prevalence, FD is associated with major uncertainties in terms of its definition, underlying pathophysiology, diagnosis, treatment, and prognosis....

AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Exp...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740554
Gastroenterology Shah SC, Piazuelo MB et. al.

Aug 30th, 2021 - The purpose of this Clinical Practice Update Expert Review is to provide clinicians with guidance on the diagnosis and management of atrophic gastritis, a common preneoplastic condition of the stomach, with a primary focus on atrophic gastritis du...

AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infect...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281326
Gastroenterology Shah SC, Iyer PG et. al.

Feb 2nd, 2021 - The purpose of this CPU Expert Review is to provide clinicians with guidance on the management of Helicobacter pylori after an initial attempt at eradication therapy fails, including best practice advice on specific regimen selection, and consider...

British Society of Gastroenterology guidelines on the diagnosis and management of patie...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709778
Gut Banks M, Graham D et. al.

Jul 7th, 2019 - Gastric adenocarcinoma carries a poor prognosis, in part due to the late stage of diagnosis. Risk factors include Helicobacter pylori infection, family history of gastric cancer-in particular, hereditary diffuse gastric cancer and pernicious anaem...

Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children...
https://doi.org/10.1097/MPG.0000000000001594
Journal of Pediatric Gastroenterology and Nutrition; Jones NL, Koletzko S et. al.

May 26th, 2017 - Because of the changing epidemiology of Helicobacter pylori infection and low efficacy of currently recommended therapies, an update of the European Society for Paediatric Gastroenterology Hepatology and Nutrition/North American Society for Pediat...

see more →

Drugs  95 results see all →

Clinicaltrials.gov  197 results

Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion
https://clinicaltrials.gov/ct2/show/NCT05762991

Mar 10th, 2023 - This study will invite patients who need to undergo urea breath test, upper gastrointestinal endoscopy and histology examination, and collect their tests results, upper gastrointestinal endoscopy images and histopathological results. We use convol...

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection
https://clinicaltrials.gov/ct2/show/NCT04713670

Mar 8th, 2023 - Background: Bismuth quadruple therapy is currently the recommended first-line regimen for Helicobacter pylori (H. pylori) infection in regions with high clarithromycin resistance. Recent randomized trials showed that 7-day vonoprazan-based triple ...

European Registry on the Management of Helicobacter Pylori Infection
https://clinicaltrials.gov/ct2/show/NCT02328131

Mar 1st, 2023 - Abstract Introduction: H. pylori selectively infects the human stomach mucosa, being the most prevalent chronic infection in the world. Its prevalence correlates with socioeconomic factors and it is higher in older individuals. H. pylori presence ...

Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection
https://clinicaltrials.gov/ct2/show/NCT05718609

Feb 16th, 2023 - The eradication rate of H. pylori is decreasing year by year due to the occurrence of bacterial resistance, especially clarithromycin, one of the most widely-used antimicrobials against H. pylori. Understanding antibiotic resistance before treatme...

New Strategy for the Detection and Treatment of Helicobacter Pylori Infections in Primary Care Guided by a Non-invasive PCR in Stool
https://clinicaltrials.gov/ct2/show/NCT05495854

Feb 14th, 2023 - In France, every year 1 million people are explored for Helicobacter pylori infection and 200,000 receive eradication treatment. Faced with the high prevalence of Hp resistance to antibiotics, the Haute Autorité de Santé (HAS) has recommended sinc...

see more →

News  161 results

Intestinal metaplasia before H. pylori eradication hints at post-eradication gastric cancer surveillance
https://www.mdedge.com/hematology-oncology/article/259671/gastrointestinal-cancer/intestinal-metaplasia-h-pylori

Nov 22nd, 2022 - Key clinical point: Patients with histological intestinal metaplasia (IM) before eradication of Helicobacter pylori infection, especially at the corpus lesser curvature, may be at an increased risk for gastric cancer after successful eradication.

Helicobacter pylori infection may predict a good response to immunotherapy in gastric cancer
https://www.mdedge.com/hematology-oncology/article/258996/gastrointestinal-cancer/helicobacter-pylori-infection-may-predict

Oct 26th, 2022 - Key clinical point: Helicobacter pylori (HP) infection is associated with the tumor expression of programmed death ligand-1 (PD-L1) in patients with gastric cancer. Major finding: HP infection was significantly associated with the tumor expression.

Vonoprazan Promising for Erosive Esophagitis
https://www.medscape.com/viewarticle/982598

Oct 18th, 2022 - The oral potassium-competitive acid blocker (PCAB) vonoprazan was noninferior and superior to the proton pump inhibitor (PPI) lansoprazole for erosive esophagitis, according to results of the phase 3 PHALCON-EE trial. Vonoprazan achieved higher ra...

Nov. 2022 - ICYMI
https://www.mdedge.com/gihepnews/article/258229/society-news/nov-2022-icymi

Sep 27th, 2022 - Gastroenterology August 2022 Johnson-Laghi KA, Mattar MC. Integrating cognitive apprenticeship into gastroenterology clinical training.

November 2022 - ICYMI
https://www.mdedge.com/gihepnews/article/258229/society-news/november-2022-icymi

Sep 27th, 2022 - Gastroenterology August 2022 Johnson-Laghi KA, Mattar MC. Integrating cognitive apprenticeship into gastroenterology clinical training.

see more →

Patient Education  5 results see all →